ArticleJournal of medicinal chemistry2026

Darizmetinib (HRX215): A Promising 1st-in-Class Liver Regenerating Drug in Phase 1b/2a Clinical Development, Targeting the Stress Signaling Protein Kinase MKK4.

Wolfgang Albrecht et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.